Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Japan Generic Market Set to Surpass 1.6 Trillion Yen by 2032: Fuji Keizai
May 17, 2024
- Xocova Forerunner in March GP Rep Promotion Rankings: Intage
May 17, 2024
- Eisai Begins Rolling Submission for Subcutaneous Leqembi in US
May 16, 2024
- Eisai Sees Global Sales of Leqembi Surging to 56.5 Billion Yen in FY2024
May 16, 2024
- Mounjaro Going Back to Normal Supply from June: Lilly/Mitsubishi
May 16, 2024
- Amgen Files BiTE Drug Tarlatamab for Lung Cancer in Japan
May 16, 2024
- As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
- Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
May 15, 2024
- Sanofi Files Sarclisa as 1st-Line Quad Therapy for MM in Japan
May 15, 2024
- Seikagaku’s Herniated Disk Drug Accepted for US FDA Review
May 15, 2024
- Sumitomo Pharma to Kick Off PI Study for Universal Flu Vaccine in Europe
May 15, 2024
- Sumitomo Seeks Label Expansion for Gemtesa in US
May 15, 2024
- Takeda, AC Immune Sign US$2 Billion Alzheimer’s Deal
May 14, 2024
- Sumitomo Pharma Replaces CEO amid Dismal Earnings
May 14, 2024
- Shionogi’s COVID-19 Pill Fails to Show Significant Difference in Global PIII
May 14, 2024
- Blackstone to Take I’rom Group Private in Bid to Address Japan’s Drug Lag
May 14, 2024
- Suzuken Eyes One-Stop Platform for Japan Launch of “Loss” Products
May 14, 2024
- Fycompa Approved for Label Expansion in China: Eisai
May 14, 2024
- Shionogi Renews Record Earnings in FY2023, Driven by Xocova and Xofluza
May 14, 2024
- Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
May 13, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…